HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress maintains existing FDA funding levels temporarily

This article was originally published in The Rose Sheet

Executive Summary

Unable to work out a deal to pass appropriations measures by the end of the fiscal year, Congress passes a continuing resolution Sept. 30, maintaining funding for FDA and other federal agencies at fiscal 2010 levels. Resolution expires Dec. 3. If Republicans win a majority in the midterm elections, they may force passage of another continuing resolution that would allow them to set spending levels in 2011 after new members take their seats. In regular appropriations legislation, the Senate Appropriations subcommittee with FDA oversight appropriated $261.5 mil. for the Center for Food Safety and Applied Nutrition and $357 mil. for the Center for Drug Evaluation and Research, both increases over last fiscal year. The House has not yet marked up its version of the agriculture appropriations bill, so funding for individual FDA centers was not known (1"The Rose Sheet" Aug. 2, 2010)

You may also be interested in...

FDA Funding Stalls As Chances Grow For Omnibus Or Continuing Resolution

The House Appropriations Committee postponed a markup of fiscal 2011 agriculture funding legislation July 27, leaving FDA's fiscal 2011 funding in limbo

BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC

The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.

BIO 2021 Notebook: Best Practices For Business Development

The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts